By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Vaxon Biotech SA 

2 rue Gaston Cremieux

Evry Genopole  Cedex  91057  France
Phone: 33-0-160789210 Fax: 33-0-160789219


SEARCH JOBS

Vaxon Biotech, based in Paris, France, is a biopharmaceutical company developing therapeutic cancer vaccines based on optimized cryptic peptides. Kostas Kosmatopoulos, Vaxon’s founder, invented the proprietary technology for effective cryptic peptide vaccines. Based on Vaxon’s optimized cryptic peptide vaccine platform, the company has developed a pipeline of therapeutic cancer vaccines, led by Vx-001, for which a Phase IIb trial has successfully completed, and Vx-006, now in Phase I development. Vaxon has received funding support from INSERM, Genopole, OSEO and the French government. Vaxon was granted orphan designation for the treatment of TERT positive NSCLC in HLA-A2 positive patients by the EMA and the FDA.

YEAR FOUNDED:

2014

LEADERSHIP:

Founder and CEO: Kostas Kosmatopoulos

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Private

Web Site: Vaxon Biotech SA
Employees:
Symbol: 
 









Company News
Vaxon Biotech SA Announces Results Of Its Phase IIb Lung Cancer Trial Of Vx-001, A Therapeutic Vaccine Based On Optimized Cryptic Peptides 6/1/2017 11:33:23 AM
Vaxon Biotech SA Publishes Article Supporting Potential Of Proprietary Optimized Cryptic Peptides As "Universal Neoantigens" 6/20/2016 10:50:50 AM
Vaxon Biotech SA Completes Enrollment Of Phase 2b Lung Cancer Trial Of First Therapeutic Vaccine Based On Optimized Cryptic Peptides 3/16/2016 9:16:09 AM
Vaxon Biotech SA Granted Japanese Patent For New Cancer Vaccine Candidates 6/22/2015 9:44:13 AM
Vaxon Biotech SA Appoints Founder And Chief Scientific Officer, Dr. Konstantinos Kosmatopoulos, As CEO 3/30/2015 9:15:48 AM
Vaxon Biotech SA Successfully Completes Its Phase I/II Trial Of Vx-001 Cancer Vaccine, Phase III Ready To Start In NSCLC 5/19/2010 11:37:46 AM
Vaxon Biotech SA Receives European Orphan Medicinal Product Designation for Vx-001 11/16/2007 11:45:19 AM
Genopole(R) And Six Of Its Campus Companies Will Attend The International Biotechnology Industry Organization (BIO) 2006 Trade Show 4/5/2006 10:47:15 AM
Vaxon-Biotech Announces Phase I Study Results for VX-001 Immunotherapy In Cancer Patients10/19/2005 5:12:24 PM
//-->